In this concise video, review recommendations for therapeutic drug monitoring of TNF-α inhibitor therapy and hear expert discussion of key data informing second-line treatment decisions of moderate to severe UC and CD following TNF-α inhibitor failure.
Progressive ILD can occur early in the disease course for patients with SSc making diagnosis and risk assessment key. New agents are available to treat inflammation and fibrosis.
Upon completion of this activity, participants should be better able to integrate new information on IPF treatment into practice as it becomes available and discuss timing and rationale for starting antifibrotic therapy.
Don’t delay the diagnosis of PAH or overlook high-risk patients who should be screened. Find out how to optimize your use of echocardiography in this activity.